HALISTER: Abbvie 4Q, Year EPS View Meet Ests.; Rev Trails on Viekira

Abbvie 4Q, Year EPS View Meet Ests.; Rev Trails on Viekira

(Bloomberg) -- AbbVie 4Q adj. EPS $1.20, est. $1.20 (range $1.18-$1.26); co. forecast $1.18-$1.20 (Oct. 28).
  • 4Q adj. rev. $6.78b vs est. $6.9b (range $6.75b-$7.07b)
    • Humira rev. $4.29b, est. $4.27b
      • Humira U.S. revenue up 23.5% y/y
    • Imbruvica rev. $511m, est. $539.6m
    • Viekira rev. $311m, est. $362.9m
  • Sees 2017 adj. EPS $5.44 to $5.54 or 13.9% growth at midpoint, saw adj. EPS growth of 13%-15% (Jan. 11), est. $5.47 (range $5.28-$5.56).
  • NOTE: Forecast excludes 89c-share of intangible asset amortization expense, other items
  • ABBV +5.7% in 2016 vs S&P 500 Health Care Index (S5HLTH) -4.4%
  • Conf. call 9am, 877-934-8565 pw ABBVIE; Preview: Humira Revenue in Cross Hairs After 3Q Miss
Statement link
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
ABBV US (AbbVie Inc)
4523 JP (Eisai Co Ltd)

To de-activate this alert, click here

UUID: 7947283